A clinical trial conducted at UNC Lineberger Comprehensive Cancer Center and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center found that high-dose cytarabine followed by subsequent immunotherapy treatment with pembrolizumab benefited patients with resistant or relapsed acute myeloid leukemia (AML), a…
Read More
Discovery provides new target to make melanomas more vulnerable to anti-cancer treatments
Hypoxia, or the inadequate oxygenation of a tissue, is a condition occurring frequently in all solid tumors such as melanoma skin cancer. Melanoma cells are not only able to survive oxygen deprivation, but also to use it to their own…
Read More
Combination immunotherapy for advanced bowel cancer approved for NHS in England
People who have previously been treated for a type of bowel cancer that has spread to other parts of their body will now have another treatment option in England, following the approval of the combined use of nivolumab (Opdivo) and…
Read More
U.S. FDA Approves ALK’s Ragwitek (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Children and Adolescents With Short Ragweed Pollen-Induced Allergic Rhinitis With or Without Conjunctivitis
ROUND ROCK, Texas, April 19, 2021 /PRNewswire/ — ALK (ALKB: DC / OMX: ALK B / AKABY / AKBLF), a global, research-driven pharmaceutical company that focuses on the diagnosis and treatment of allergies, announced that the U.S. Food and Drug…
Read More
Cancer immunotherapy may also treat certain autoimmune diseases
A team of researchers has found disrupting the interaction between cancer cells and certain immune cells is more effective at killing cancer cells than current immunotherapy treatments. The findings, which include studies in cell lines and animal models, appeared in…
Read More
Phase 3 DREAM3R trial opens for malignant pleural mesothelioma
The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand. The DREAM3R study builds on signals of effectiveness found in independent single-arm phase two trials,…
Read More
Studies reveal the promise of newly engineered bispecific antibodies against tumor cells
Three studies – one each in Science, Science Translational Medicine, and Science Immunology – reveal the promise of newly engineered bispecific antibodies, including by demonstrating their power against previously inaccessible tumor cell targets for the first time, in two cases….
Read More
FDA Approves Libtayo (cemiplimab-rwlc) as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
TARRYTOWN, N.Y. and PARIS, Feb. 9, 2021 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) as the first immunotherapy treatment indicated for patients with…
Read More
Scientists unlock promising key to preventing cancer relapse after immunotherapy
Mount Sinai researchers have solved one of the enduring mysteries of cancer immunotherapy: Why does it completely eliminate tumors in many patients, even when not all the cells in those tumors have the molecular target that the therapy is aimed…
Read More
Immunotherapy offers hope for prostate cancer treatment
An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant prostate cancer. This is the finding of the long-term analyses of an international phase 3 clinical trial, recently published in the journal European Urology. The…
Read More